# Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Source: https://nuclide.cc/trials/nct04724369/  
Nuclide record `nct04724369` (Trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of 18F-MFBG in neuroblastoma, run by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), active and no longer recruiting.

## Summary

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma is a phase 3 interventional study registered as NCT04724369 by Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC), with 43 participants enrolled, started 2021-11-18 and due to reach its primary completion in 2026-07-30. Interventions recorded: 18F-MFBG.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04724369
- Phase: 3
- Setting: A Prospective Phase 3 Multi-center Study to Assess the Efficacy and Safety of 18F-mFBG PET Imaging in Subjects With Neuroblastoma
- Sponsor: Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- Enrolled: 43

## Sources

- ClinicalTrials.gov NCT04724369: https://clinicaltrials.gov/study/NCT04724369

## Connected records

- isotopes: [Fluorine-18](https://nuclide.cc/isotopes/f-18/)
- indications: [Neuroblastoma (paediatric)](https://nuclide.cc/indications/neuroblastoma/)
- technologies: [PET (positron emission tomography)](https://nuclide.cc/technologies/pet/)
- targets: [Norepinephrine transporter (NET)](https://nuclide.cc/targets/norepinephrine-transporter/)

---
JSON: https://nuclide.cc/api/v1/entities/nct04724369.json